Anthony Culverwell Biography and Net Worth

Director of Quoin Pharmaceuticals

Mr. Culverwell has served as a director of Quoin Inc. since April 2021 and as a director of Quoin Ltd. since October 28, 2021. He is also currently serving as the Chief Executive Officer and Chairman of the Board of Directors of HOX Therapeutics. He serves as a director and Audit Committee Chairman of TC BioPharm (Holdings) plc (Nasdaq: TCBP) and he serves as a director, Audit Committee Chairman, and member of the Compensation Committee of SafeGuard Biosystems. In 2005, Mr. Culverwell founded Sudbrook Associates, which provided strategic advice and fundraising services for life science companies. Previously, Mr. Culverwell was Senior Vice President and Global Coordinator Healthcare Research at Merrill Lynch. He also served as Director of Healthcare Equity Research at ABN Amro Bank N.V., director and Audit Committee Chairman of Amryt Pharma PLC (Nasdaq: AMYT), and director and Audit Committee Chairman of Innocoll AG. He received an MSc with honors from the University of Aberdeen.

What is Anthony James Culverwell's net worth?: The estimated net worth of Anthony James Culverwell is at least $190.52 thousand as of August 31st, 2026. Mr. Culverwell owns 40,364 shares of Quoin Pharmaceuticals stock worth more than $190,518 as of October 7th. This net worth estimate does not reflect any other investments that Mr. Culverwell may own. Learn More about Anthony James Culverwell's net worth.
How do I contact Anthony James Culverwell?: The corporate mailing address for Mr. Culverwell and other Quoin Pharmaceuticals executives is 23 Hata'as Street, Kfar Saba, 44425. Quoin Pharmaceuticals can also be reached via phone at +97299741444 and via email at [email protected]. Learn More on Anthony James Culverwell's contact information.
Has Anthony James Culverwell been buying or selling shares of Quoin Pharmaceuticals?: Anthony James Culverwell has not been actively trading shares of Quoin Pharmaceuticals during the last ninety days. Most recently, on Monday, August 31st, Anthony James Culverwell bought 6,146 shares of Quoin Pharmaceuticals stock. The stock was acquired at an average cost of $4.88 per share, with a total value of $29,992.48. Following the completion of the transaction, the director now directly owns 40,364 shares of the company's stock, valued at $196,976.32. Learn More on Anthony James Culverwell's trading history.
Who are Quoin Pharmaceuticals' active insiders?: Quoin Pharmaceuticals' insider roster includes Denise Carter (COO), Anthony Culverwell (Director), Gordon Dunn (CFO), Dennis Langer (Director), Sally Lawlor (CFO), and Michael Myers (CEO). Learn More on Quoin Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Quoin Pharmaceuticals?: In the last twelve months, Quoin Pharmaceuticals insiders bought shares 5 times. They purchased a total of 72,522 shares worth more than $408,606.08. The most recent insider tranaction occured on August, 31st when COO Denise P. Carter bought 20,490 shares worth more than $99,991.20. Insiders at Quoin Pharmaceuticals own 11.2% of the company. Learn More about insider trades at Quoin Pharmaceuticals.
Information on this page was last updated on 8/31/2026.

Anthony James Culverwell Insider Trading History at Quoin Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/31/2026	Buy	6,146	$4.88	$29,992.48	40,364
12/23/2024	Buy	2,857	$15.75	$44,997.75	2,866

Anthony James Culverwell Buying and Selling Activity at Quoin Pharmaceuticals

Quoin Pharmaceuticals Company Overview

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

Today's Range

Now: $4.62

$4.51

$4.79

50 Day Range

MA: $5.73

$4.26

$7.87

2 Week Range

Now: $4.62

$3.25

$41.80

Volume

3,610 shs

Average Volume

292,420 shs

Market Capitalization

$9.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56